» Articles » PMID: 29450576

ImmunoPET Imaging of CD38 in Murine Lymphoma Models Using Zr-labeled Daratumumab

Overview
Date 2018 Feb 17
PMID 29450576
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: CD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with Zr-labeled daratumumab was used for differentiation of CD38 expression in murine lymphoma models to provide a potential non-invasive method for monitoring CD38 in the clinic.

Methods: Daratumumab was radiolabeled with Zr (t = 78.4 h) via conjugation with desferrioxamine (Df). After Western blot (WB) was used to screen CD38 expression in five lymphoma cell lines, flow cytometry and cellular binding assays were performed to test the binding ability of labeled or conjugated daratumumab with CD38 in vitro. PET imaging and biodistribution studies were performed to evaluate CD38 expression after injection of Zr-Df-daratumumab. Zr-Df-IgG was also evaluated as a non-specific control group in the Ramos model. Finally, CD38 expression in tumor tissues was verified by histological analysis.

Results: Using WB screening, the Ramos cell line was found to express the highest level of CD38 while the HBL-1 cell line had the lowest expression. Df-conjugated and Zr-labeled daratumumab displayed similar high binding affinities with Ramos cells. PET imaging of Zr-Df-daratumumab showed a high tumor uptake of up to 26.6 ± 8.0 %ID/g for Ramos at 120 h post-injection, and only up to 6.6 ± 2.9 %ID/g for HBL-1 (n = 4). Additionally, Zr-Df-IgG demonstrated a low tumor uptake in the Ramos model (only 4.3 ± 0.8 %ID/g at 120 h post-injection). Ex vivo biodistribution studies showed similar trends with imaging results. Immunofluorescence staining of tumor tissues verified higher CD38 expression of Ramos than that of HBL-1.

Conclusions: The role of Zr-Df-daratumumab was investigated for evaluating CD38 expression in lymphoma models non-invasively and was found to be to a promising imaging agent of CD38-positive hematological diseases such as MM in future clinical applications.

Citing Articles

Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.

Huang W, Li L, Zhou Y, Yang Q, Mixdorf J, Barnhart T Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39878898 DOI: 10.1007/s00259-025-07106-4.


CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.

Huang W, Wang T, Qiu Y, Li C, Chen B, Song L Eur J Nucl Med Mol Imaging. 2024; .

PMID: 39725695 DOI: 10.1007/s00259-024-07036-7.


CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity.

Imbery J, Wiik C, Heinzelbecker J, Jebsen J, Dobbing M, Bottini N Mol Ther Oncol. 2024; 32(3):200841.

PMID: 39474602 PMC: 11519781. DOI: 10.1016/j.omton.2024.200841.


Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging.

Zhang L, Zhao L, Lin X, Zhao S, Pan W, Wang D Mol Imaging. 2024; 23:15353508241261473.

PMID: 38952401 PMC: 11208884. DOI: 10.1177/15353508241261473.


Modeling the subcutaneous pharmacokinetics of antibodies co-administered with rHuPH20.

Nolan R, Printz M Clin Transl Sci. 2024; 17(4):e13788.

PMID: 38561908 PMC: 10985223. DOI: 10.1111/cts.13788.


References
1.
Bartel T, Haessler J, Brown T, Shaughnessy Jr J, van Rhee F, Anaissie E . F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009; 114(10):2068-76. PMC: 2744568. DOI: 10.1182/blood-2009-03-213280. View

2.
Ak I, Aslan V, Vardareli E, Gulbas Z . Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells. Ann Hematol. 2003; 82(2):88-92. DOI: 10.1007/s00277-002-0600-2. View

3.
Pavon E, Zumaquero E, Rosal-Vela A, Khoo K, Cerezo-Wallis D, Garcia-Rodriguez S . Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Cytokine. 2013; 62(2):232-43. DOI: 10.1016/j.cyto.2013.02.023. View

4.
de Waal E, Glaudemans A, Schroder C, Vellenga E, Slart R . Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting. Eur J Nucl Med Mol Imaging. 2016; 44(2):332-341. PMC: 5215256. DOI: 10.1007/s00259-016-3576-1. View

5.
Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View